CNTB PE Ratio & Valuation,Is CNTB Overvalued

CNTB Relative Valuation

CNTB's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, CNTB is overvalued; if below, it's undervalued.

Historical Valuation

Connect Biopharma Holdings Ltd (CNTB) is now in the Fair zone, suggesting that its current forward PS ratio of 46350.70 is considered Fairly compared with the five-year average of -3.50. The fair price of Connect Biopharma Holdings Ltd (CNTB) is between -- to -- according to relative valuation methord.

Relative Value

Fair Zone

-----

Current Price：2.50

Fair

-1.93

0.00

EV/EBITDA

Connect Biopharma Holdings Ltd. (CNTB) has a current EV/EBITDA of 0.00. The 5-year average EV/EBITDA is -2.44. The thresholds are as follows: Strongly Undervalued below -15.55, Undervalued between -15.55 and -9.00, Fairly Valued between 4.11 and -9.00, Overvalued between 4.11 and 10.66, and Strongly Overvalued above 10.66. The current Forward EV/EBITDA of 0.00 falls within the Historic Trend Line -Fairly Valued range.

-1.15

EV/EBIT

Connect Biopharma Holdings Ltd. (CNTB) has a current EV/EBIT of -1.15. The 5-year average EV/EBIT is -0.17. The thresholds are as follows: Strongly Undervalued below -8.20, Undervalued between -8.20 and -4.18, Fairly Valued between 3.84 and -4.18, Overvalued between 3.84 and 7.85, and Strongly Overvalued above 7.85. The current Forward EV/EBIT of -1.15 falls within the Historic Trend Line -Fairly Valued range.

46289.03

Connect Biopharma Holdings Ltd. (CNTB) has a current PS of 46289.03. The 5-year average PS is 1604.86. The thresholds are as follows: Strongly Undervalued below -13935.92, Undervalued between -13935.92 and -6165.53, Fairly Valued between 9375.25 and -6165.53, Overvalued between 9375.25 and 17145.64, and Strongly Overvalued above 17145.64. The current Forward PS of 46289.03 falls within the Strongly Overvalued range.

-2.98

P/OCF

Connect Biopharma Holdings Ltd. (CNTB) has a current P/OCF of -2.98. The 5-year average P/OCF is -0.59. The thresholds are as follows: Strongly Undervalued below -4.21, Undervalued between -4.21 and -2.40, Fairly Valued between 1.22 and -2.40, Overvalued between 1.22 and 3.04, and Strongly Overvalued above 3.04. The current Forward P/OCF of -2.98 falls within the Undervalued range.

0.00

P/FCF

Connect Biopharma Holdings Ltd. (CNTB) has a current P/FCF of 0.00. The 5-year average P/FCF is -1.40. The thresholds are as follows: Strongly Undervalued below -10.54, Undervalued between -10.54 and -5.97, Fairly Valued between 3.17 and -5.97, Overvalued between 3.17 and 7.74, and Strongly Overvalued above 7.74. The current Forward P/FCF of 0.00 falls within the Historic Trend Line -Fairly Valued range.

Connect Biopharma Holdings Ltd (CNTB) has a current Price-to-Book (P/B) ratio of 2.50. Compared to its 3-year average P/B ratio of 0.73 , the current P/B ratio is approximately 244.40% higher. Relative to its 5-year average P/B ratio of 1.01, the current P/B ratio is about 147.34% higher. Connect Biopharma Holdings Ltd (CNTB) has a Forward Free Cash Flow (FCF) yield of approximately -30.77%. Compared to its 3-year average FCF yield of -88.10%, the current FCF yield is approximately -65.07% lower. Relative to its 5-year average FCF yield of -86.16% , the current FCF yield is about -64.29% lower.

2.50

P/B

Median3y

0.73

Median5y

1.01

-30.77

FCF Yield

Median3y

-88.10

Median5y

-86.16

Competitors Valuation Multiple

The average P/S ratio for CNTB's competitors is 7723.05, providing a benchmark for relative valuation. Connect Biopharma Holdings Ltd Corp (CNTB) exhibits a P/S ratio of 46289.03, which is 499.36% above the industry average. Given its robust revenue growth of -98.69%, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

Revenue Growth

Market Cap

Performance Decomposition

Market capitalization of CNTB increased by 81.16% over the past 1 year. The primary factor behind the change was an decrease in Margin Expansion from -1.06K to -107.50K.

The secondary factor is the Revenue Growth, contributed -98.69%to the performance.

Overall, the performance of CNTB in the past 1 year is driven by Margin Expansion. Which is more sustainable.

-98.69%

1.22M → 16.00K

Revenue Growth

10077.23%

-1.06K → -107.50K

Margin Expansion

-9897.38%

0.03 → -2.79

P/E Change

81.16%

1.38 → 2.50

Mkt Cap Growth

People Also Watch

Frequently Asked Questions

Is Connect Biopharma Holdings Ltd (CNTB) currently overvalued or undervalued?

What is Connect Biopharma Holdings Ltd (CNTB) fair value?

CNTB's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Connect Biopharma Holdings Ltd (CNTB) is between to according to relative valuation methord.

How does CNTB's valuation metrics compare to the industry average?

What is the current P/B ratio for Connect Biopharma Holdings Ltd (CNTB) as of Dec 15 2025?

As of Dec 15 2025, Connect Biopharma Holdings Ltd (CNTB) has a P/B ratio of 2.50. This indicates that the market values CNTB at 2.50 times its book value.

What is the current FCF Yield for Connect Biopharma Holdings Ltd (CNTB) as of Dec 15 2025?

As of Dec 15 2025, Connect Biopharma Holdings Ltd (CNTB) has a FCF Yield of -30.77%. This means that for every dollar of Connect Biopharma Holdings Ltd’s market capitalization, the company generates -30.77 cents in free cash flow.

What is the current Forward P/E ratio for Connect Biopharma Holdings Ltd (CNTB) as of Dec 15 2025?

As of Dec 15 2025, Connect Biopharma Holdings Ltd (CNTB) has a Forward P/E ratio of -1.93. This means the market is willing to pay $-1.93 for every dollar of Connect Biopharma Holdings Ltd’s expected earnings over the next 12 months.

What is the current Forward P/S ratio for Connect Biopharma Holdings Ltd (CNTB) as of Dec 15 2025?

As of Dec 15 2025, Connect Biopharma Holdings Ltd (CNTB) has a Forward P/S ratio of 46350.70. This means the market is valuing CNTB at $46350.70 for every dollar of expected revenue over the next 12 months.

CNTB Valuation